John Oncea

buck25.bsky.social

22 October 2026 13:46

Two articles with Liam Devenish explore hidden costs and lessons from South Africa’s trial sites. Read both via the companion link: www.clinicaltechleader.com/doc/what-sou...

John Oncea

buck25.bsky.social

20 October 2026 14:59

An impressive model can still answer a poorly defined question. Start with what you need to learn. Challenge your assumptions. Know when to involve a biostatistician. Analytical capability includes recognizing where your expertise ends. www.clinicaltechleader.com/doc/research...

John Oncea

buck25.bsky.social

19 October 2026 13:26

Virtua Health is approaching a million imaging exams a year, with 1.5 million projected. My conversation with Laura Patrone explores the work behind that growth: vendor security, EHR integration, and workflows that still need human attention. www.clinicaltechleader.com/doc/the-infr...

John Oncea

buck25.bsky.social

15 October 2026 13:41

AI adoption in clinical research may not follow the usual generational pattern. Younger researchers question AI’s purpose and governance, not just its usability. The question isn't can we use AI; it’s for what? www.clinicaltechleader.com/doc/a-framew... www.clinicaltechleader.com/doc/why-youn...

John Oncea

buck25.bsky.social

14 October 2026 12:59

Accelerated approval should compress a well-designed evidence plan, not replace one. Skipping dose-response work does not eliminate the question. It moves it to Phase 3 or after approval, where the cost of getting it wrong is higher. www.clinicaltechleader.com/doc/inside-t...